Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.
Michael Untch, MD, PhD, professor, chief physician, Obstetrics and Gynecology, Helios Hospital Berlin-Buch, Berlin, Germany, discusses the widespread use of biosimilars in Europe.
Following the introduction of ABP 980 (Kanjinti; trastuzumab-anns), a biosimilar for trastuzumab (Herceptin) over 1 year ago, biosimilars have gained traction in Germany, explains Untch. Now, several additional biosimilars for trastuzumab have been approved in Europe.
Biosimilars are used widely in Europe, says Untch. He suggests that the money saved from using biosimilars could be redirected to further research and therapeutic development for patients.
Although there is still some resistance toward biosimilars in the United States, Untch is certain their adoption in Europe will continue to expand as more biosimilars are introduced.